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BACKGROUND: Endometriosis is typically regarded as a premenopausal disease, resolving after natural or iatrogenic menopause due to
declining oestrogen levels. Nonetheless, case reports over the years have highlighted the incidence of recurrent postmenopausal endomet-
riosis. It is now clear that both recurrence and malignant transformation of endometriotic foci can occur in the postmenopausal period.
Postmenopausal women are commonly treated with hormone replacement therapy (HRT) to treat climacteric symptoms and prevent
bone loss; however, HRT may reactivate endometriosis and stimulate malignant transformation in women with a history of endometriosis.
Given the uncertain risks of initiating HRT, it is difficult to determine the best menopausal management for this group of women.
OBJECTIVE AND RATIONAL: The aim of this study was to systematically review the existing literature on management of meno-
pausal symptoms in women with a history of endometriosis. We also aimed to evaluate the published literature on the risks associated
with HRT in these women, and details regarding optimal formulations and timing (i.e. initiation and duration) of HRT.
SEARCH METHODS: Four electronic databases (MEDLINE via OVID, Embase via OVID, PsycINFO via OVID and CINAHL via
EbscoHost) were searched from database inception until June 2016, using a combination of relevant controlled vocabulary terms and free-
text terms related to ‘menopause’ and ‘endometriosis’. Inclusion criteria were: menopausal women with a history of endometriosis and
menopausal treatment including HRT or other preparations. Case reports/series, observational studies and clinical trials were included.
Narrative review articles, organizational guidelines and conference abstracts were excluded, as were studies that did not report on any
form of menopausal management. Articles were assessed for risk of bias and quality using GRADE criteria.
OUTCOMES: We present a synthesis of the existing case reports of endometriosis recurrence or malignant transformation in women
undergoing treatment for menopausal symptoms. We highlight common presenting symptoms, potential risk factors and outcomes
amongst the studies. Sparse high-quality evidence was identified, with few observational studies and only two randomized controlled trials.
Given this paucity of data, no definitive conclusions can be drawn concerning risk.
WIDER IMPLICATIONS: Due to the lack of high-quality studies, it remains unclear how to advise women with a history of endometri-
osis regarding the management of menopausal symptoms. The absolute risk of disease recurrence and malignant transformation cannot be
quantified, and the impact of HRT use on these outcomes is not known. Multicentre randomized trials or large observational studies are
urgently needed to inform clinicians and patients alike.
Key words: endometriosis / menopause / HRT / unopposed oestrogen / combined HRT / tibolone / recurrence / malignant
transformation
Introduction
Endometriosis and oestrogen dependence
Endometriosis is a disease that affects an estimated 6–10% of repro-
ductive aged women, totalling approximately 176 million women
worldwide (Bulun, 2009). It is defined as the presence of endometrial-
like tissue in extrauterine locations and is a chronic condition associated
with debilitating pelvic pain, dyspareunia, dysuria, dysmenorrhoea and
infertility. However, due to a lack of reliable diagnostic tools and the
non-specific nature of the symptoms, there exists a widely recognized
delay in diagnosis of 8–10 years (Ahn et al., 2017). Consequently, the
economic impact is substantial, as chronic and debilitating pain from
endometriosis may hinder work productivity, while infertility can cause
major psychosocial and financial strain to affected women and their
partners (Simoens et al., 2007, 2012).
The pathophysiology of endometriosis is complex and not com-
pletely understood. Sampson’s retrograde menstruation theory, which
states that endometrial cells travel backwards through the fallopian
tubes during menses to reach the peritoneal cavity, has gathered the
most robust support (Vercellini et al., 2014). Oestrogen dependence,
progesterone resistance, inflammation and genetic predisposition
represent some of the pathophysiological hallmarks of this disease
(Burney and Giudice, 2012). The central feature is oestrogen-
dependent growth. Endometriotic lesions pathologically overexpress
oestrogen receptor beta (ERβ) (>100× higher expression compared
to endometrial tissue) and have been demonstrated to express (i) high
levels of steroidogenic acute regulatory protein (StAR) and P450
aromatase, and (ii) reduced levels of 17beta hydroxysteroid dehydro-
genase Type 2. This expression profile results in locally elevated levels
of the biologically active form of oestrogen (oestradiol) (Kitawaki et al.,
2002; Bulun et al., 2012). These molecular studies are supported by
clinical observations of disease regression, symptom relief and alleged
‘cures’ for endometriosis as women achieve a hypo-oestrogenic state
through iatrogenic or natural menopause (Inceboz, 2015).
Transition to menopause
Understanding the altered hormonal milieu in endometriosis has
enabled clinicians to exploit oestrogen dependence in their manage-
ment, prescribing medications to suppress ovarian function or alter
local oestrogenic effects. However, in severely symptomatic cases,
first-line medical therapy (including the oral contraceptive pill or pro-
gestogens) or laparoscopic excision of endometriotic lesions may
prove insufficient, and induction of menopause via GnRH analogues
or oophorectomy is indicated (Dunselman et al., 2014). Surgically or
medically induced menopause is associated with a swift and dramatic
fall in oestrogen levels. This decline may relieve endometriosis-
related symptoms, but can simultaneously trigger menopausal symp-
toms. These symptoms are diverse and include hot flushes, vaginal
dryness, sleep and mood disturbances, night sweats and painful inter-
course, among others. While these symptoms occur in many women
who naturally transition into menopause, they are especially prevalent
and severe in women with a sudden onset of the hypoestrogenic
state (Hendrix, 2005). The gold standard for treatment of
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menopausal symptoms has traditionally been hormone replacement
therapy (HRT). HRT has been crucial for achieving symptom relief
and improving the quality of life of millions of menopausal women,
although these successes have been accompanied by safety concerns
regarding specific preparations and dosages (Manson et al., 2013).
Appropriateness of HRT
Many studies have explored the efficacy and safety of HRT in post-
menopausal women with climacteric symptoms (Rossouw et al.,
2002; Rozenberg et al., 2013); however, few studies have investigated
the use of hormonal therapy in postmenopausal women with a his-
tory of endometriosis. Two specific concerns are present in this
group of women. Firstly, there is the possibility that exogenous oes-
trogen will reactivate growth of endometriotic deposits and cause
symptomatic recurrence. Secondly, there is a concern that oestrogen
will promote malignant transformation of residual endometriotic tis-
sue. Sampson first described malignant transformation of ovarian
endometriosis in 1925 (Sampson, 1925) and although its pathogenesis
is not fully understood, oxidative stress, inflammation and an altered
hormonal milieu have been implicated as contributing factors (Nezhat
et al., 2014). Malignant transformation is thought to be a multistep
pathway in which normal endometriotic tissue progresses to an atyp-
ical intermediate stage, and finally to invasive carcinoma (Gadducci
et al., 2014). These sequential steps towards malignancy have been asso-
ciated with genetic alternations in PTEN, TP53 and ARID1A and have
been demonstrated in endometriosis-associated cancers (Munksgaard
and Blaakaer, 2012). In a recent animal study using a rodent model of
endometriosis (adult female Sprague-Dawley rats, aged 8–12 weeks),
treatment with unopposed oestrogen successfully induced malignant
transformation of endometriotic foci (Wang et al., 2015). Mechanistically,
oestrogens affect PTEN expression in human endometrial cells and are
associated with increased proliferation, direct cell damage and increased
risk of acquiring somatic mutations (Turbiner et al., 2008).
However, the impact of declining oestrogen levels should not be
underestimated. Menopausal symptoms affect the lives of millions of
women worldwide. The hypo-oestrogenic state can significantly impair
the quality of life by making sexual intercourse uncomfortable or pain-
ful, causing sleep deprivation, or resulting in mood changes.
Furthermore, declining systemic oestrogen levels are a risk factor for
cardiovascular and bone disease (Gallagher, 2007; Rosano et al., 2007).
The use of HRT has been shown to reduce the risk of such conditions
and improve the quality of life of symptomatic women (Langer, 2017).
The decision whether or not to prescribe HRT in general, and par-
ticularly in women with a history of endometriosis, is therefore a com-
plex clinical decision and may also take into account other risk factors,
such as residual disease after surgery (Clayton et al., 1999) and obesity
which causes increased aromatase activity in peripheral tissues resulting
in higher systemic oestrogen levels (Zanetta et al., 2000).
Our study aimed to conduct a systematic review of the literature
investigating a critical question: What is the current evidence on the
management of menopausal symptoms in women with a history of
endometriosis? We aimed to cover the literature on a number of
sub-questions, including: What are the various treatment options to
manage menopausal symptoms in these women? What are the risks
associated with HRT in this cohort? Should HRT be given immedi-
ately following surgically induced menopause or be delayed? What
preparations are most appropriate, and for how long should treat-
ment be given? We aimed to synthesize the literature in a compre-
hensive manner, and hoped to aid the design of future research in
this area. Given the prevalence of endometriosis and the inevitability
of eventual menopause in these women, this is clearly an important
question that warrants robust, evidence-based guidelines.
Methods
This systematic review was registered and accepted for inclusion in
PROSPERO (Gemmell et al., 2016) in July 2016 (PROSPERO ID number:
CRD42016042024).
Search strategy
We searched four electronic databases (MEDLINE via OVID, Embase via
OVID, PsycINFO via OVID and CINAHL via EbscoHost), from database
inception until 26 June 2016, using a combination of relevant controlled
vocabulary terms and free-text terms searched in the title or abstract
fields related to ‘menopause’ and ‘endometriosis’. No study type, lan-
guage or date limits were applied to the search. An example of the
search strategy used for the MEDLINE database is included in
Supplementary Table S1.
Inclusion criteria
All retrieved studies were uploaded to EndNote and duplicates were
deleted. One reviewer (L.G.) sifted the full library (titles/abstracts), and
two reviewers (K.W., C.B.) sifted 10% of the library (randomly selected
using EndNote Record Number) to assess concordance. The full text of
potentially relevant articles was retrieved to assess whether the paper
should be included. Inclusion criteria were that the study population
included postmenopausal women with a confirmed, or clinically sus-
pected, history of endometriosis, and the article discussed management
of menopausal symptoms. All study designs were included (case reports,
observational studies and clinical trials). We excluded articles that did not
discuss any form of menopausal management (e.g. HRT, tibolone or
other preparations). We excluded narrative review articles and organiza-
tional guidelines in an attempt to focus the review on primary literature.
Conference abstracts were also excluded.
The reviewers shared their lists of included studies, and concordance
was determined. When there were disparities in the list, consensus was
reached through discussions between the reviewers.
Quality assessment
Quality of included studies was assessed independently by two reviewers
(L.G., K.W.) using the GRADE criteria (Guyatt et al., 2011). Assigned rat-
ings were compared and a third reviewer (C.B.) was consulted when
there were disagreements.
Data extraction
Data were extracted into a standard form by one reviewer (L.G). For
case reports, the following information was extracted: patient age at
presentation, presenting symptoms, ureteral involvement (yes or no),
type (surgical vs. natural) and timing (years previously) of menopause,
stage and extent of endometriosis before menopause, reported meno-
pausal symptoms, treatment provided, duration of follow-up, method of
outcome assessment, outcome (recurrence, malignant transformation,
side effects, mortality) and recommendation (if provided).
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For all other study types, information on study design, study objective,
sample size, participants’ characteristics, intervention, method of out-
come assessment, outcome, duration of follow-up and recommendation
(if provided) was recorded.
Data synthesis and analysis
The nature of the evidence retrieved by our search (predominantly case
reports, and a small number of heterogeneous observational studies and
clinical trials) meant that meta-analysis was not possible, thus a narrative
synthesis of the data is provided.
Where possible, if not reported in the original article, risk ratios (RRs)
for specific outcomes were calculated using RevMan (Review Manager
(RevMan) [Computer program]. Version 5.3 2014).
Results
Included studies
Searches across all four databases retrieved 17 488 studies.
Duplicates (5008) were removed, leaving 12 480 studies (Fig. 1).
After reading titles and abstracts, 12 366 failed to meet inclusion cri-
teria. The full-text versions of the remaining 114 studies were read in
their entirety. Of these 114 studies, 75 were excluded because they
did not meet our inclusion criteria. This left 39 included studies: 33
case reports and 6 observational studies and clinical trials.
The majority of relevant articles identified by the search were indi-
vidual case reports or case series describing the recurrence of endo-
metriosis or malignant transformation in postmenopausal women. A
small number of observational studies and clinical trials were also
identified. We first present a summary of the data from case reports
and case series to give context, before describing the results of the
observational cohorts and trials.
Case reports and case series (33 studies;
48 patients)
There were 32 case reports/series including 42 patients identified by
our search. An additional article describing endometriosis-related
malignancies in six women who had taken oestrogen replacement
was retrieved (Leiserowitz et al., 2003). This article is discussed sep-
arately, as insufficient data are reported for the individual women to
enable inclusion in our summary statistics.
Outcome evidence provided by these reports was assessed as
very low quality given their observational nature and inherent risk of
publication bias. Summary characteristics of the 42 patients are pre-
sented in Table I. The age of included patients ranged between 30
and 75 years at presentation (mean age: 52 years). Of 42 patients, 40
had prior histories of endometriosis, either (i) confirmed by intrao-
perative visualization and/or histologically after laparoscopic excision
(n = 34), (ii) suspected given the presence of symptoms (infertility,
Figure 1 Flow diagram depicting inclusion and exclusion decisions throughout the review process.
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pelvic pain, menorrhagia) (n = 2), or (iii) assessed by unspecified
methodology (n = 4). Two patients did not have premenopausal
endometriosis diagnoses, but were speculated by the case report
authors to have had such and are thus included in our analysis. There
were 36 patients who went through a surgically induced menopause
(procedures involving oophorectomy), and four patients went
through menopause naturally (one of these four was diagnosed with
premature ovarian insufficiency). An additional two patients are
believed to have gone through natural menopause, and underwent
oophorectomy at ages 57 and 60. HRT was given as treatment for
(n = 12) or prevention of (n = 30) menopausal symptoms. The mean
duration of HRT use prior to presentation was 7.8 years (range: 4
months to 20 years). Of 36 patients who had undergone hysterec-
tomy, 31 used unopposed oestrogen therapy.
The two main outcomes reported were endometriosis recurrence
(n = 17) and malignant transformation (n = 25). For analysis, case
reports and series were divided by these two main outcomes. One
case series was included in both outcomes as it described three
patients with endometriosis recurrence and one patient with malig-
nant transformation (Taylor et al., 1999).
Endometriosis recurrence in women
on HRT (17 patients)
Thirteen case reports and case series were identified reporting endo-
metriosis recurrence in menopausal women given HRT for the treat-
ment or prevention of menopausal symptoms. These included 17
patients between the ages of 30–65 (median age: 46 years) (Table II).
All of the included women had undergone treatment with exogenous
oestrogens in some form. Skor et al. (1977) was the earliest report
retrieved by our search. This case was a 48-year-old Caucasian
woman who presented with a 2-month history of painless haematuria
and decreased urinary stream on voiding. She had undergone a total
abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH +
BSO) with endometriosis found in the specimen and confirmed by hist-
ology. She had been prescribed conjugated oestrogens (Premarin
1.25mg/day) following surgery and continued these for 6 years until
her presentation. On physical examination, a 7 cm × 8 cm mass starting
in the midline and extending to the left pelvic wall was palpated and
the patient underwent cystoscopy. Postmenopausal bladder endomet-
riosis was diagnosed histologically. Oestrogens were discontinued and
intramuscular medroxyprogesterone acetate (1 gm per week) was
administered for 2 months. Despite this, there was no significant alter-
ation in the size of the mass. Shortly afterwards, due to symptom
recurrence, the endometriotic lesion was removed surgically. The
patient had no complaints 1-year post treatment. The authors com-
mented that exogenous oestrogens play a role in the stimulation and
development of postmenopausal endometriosis.
Sixteen other similar accounts were retrieved from our search,
with the latest report published in 2009 (Giarenis et al., 2009). The
majority of cases (12 out of 17) were women with a prior hysterec-
tomy, who took unopposed oestrogen. The remaining cases of recur-
rence were in women who took combined HRT.
Severity of prior endometriosis and menopause
Six patients had a history of ‘extensive’ or ‘severe’ endometriosis
(Manyonda et al., 1989; Joseph et al., 1994; Taylor et al., 1999;
Badawy et al., 2004). Fourteen patients underwent surgical meno-
pause years before presentation (Skor et al., 1977; Stewart and
Ireland, 1977; Kapadia et al., 1984; Ray et al., 1985; Manyonda et al.,
1989; Joseph et al., 1994; Taylor et al., 1999, 2005; Badawy et al.,
2004; Giarenis et al., 2009), while only two transitioned naturally to
menopause (Goh and Hall, 1992; Chahine et al., 2007). One patient
entered menopause as a result of premature ovarian insufficiency
(Mattar et al., 2008). The median time between surgical menopause
and presentation was 7.1 years (range: 4 months to 13 years).
Menopausal management
Unopposed oestrogen was implicated in numerous cases of symptom
recurrence (n = 12) (Skor et al., 1977; Stewart and Ireland, 1977;
Kapadia et al., 1984; Ray et al., 1985; Manyonda et al., 1989; Taylor
et al., 1999, 2005; Badawy et al., 2004; Giarenis et al., 2009). Fewer
studies reported recurrence in women who were using combined
hormonal preparations (oestrogen and progestagen) (n = 5) (Goh
and Hall, 1992; Joseph et al., 1994; Badawy et al., 2004; Chahine
et al., 2007; Mattar et al., 2008). In terms of method of oestrogen
administration, oral tablets (n = 5) (Skor et al., 1977; Stewart and
Ireland, 1977; Kapadia et al., 1984; Ray et al., 1985; Goh and Hall,
1992), implants (n = 6) (Manyonda et al., 1989; Taylor et al., 1999,
2005) and patches (n = 3) (Badawy et al., 2004; Taylor et al., 2005)
were all reported. Table III provides information on HRT dosages
and regimens; however, variability in the level of detail provided by
the included case reports and series limits these data.
Presenting symptoms and sites of recurrence
As may be expected, endometriosis recurrence commonly presented
with pain (n = 7): in locations typical of premenopausal endometriosis, i.e.
abdomen (Taylor et al., 1999), iliac fossae (Manyonda et al., 1989;
Goh and Hall, 1992), genitals (Taylor et al., 1999); and in more
unusual sites such as the loin (Manyonda et al., 1989). Abnormal bleed-
ing was also a common presentation (n = 14), including postmenopau-
sal vaginal bleeding (Taylor et al., 1999; Badawy et al., 2004; Giarenis
et al., 2009), haematuria (Skor et al., 1977; Stewart and Ireland, 1977;
Kapadia et al., 1984; Ray et al., 1985; Taylor et al., 2005), rectal bleed-
ing (Taylor et al., 2005) and also haemoptysis (Joseph et al., 1994;
........................................................................................
Table I Summary characteristics from case reports
and series.
Case reports and series (GRADE (Guyatt et al., 2011) scoring:
very low quality)
Number of patients (n) 42
Age range (years) (mean (years)) 30–75 (52)
Type of menopause (n) Surgical: 36
Natural: 4
Presumed natural + oophorectomy
later: 2
Mean duration of HRT (years) 7.8
Unopposed oestrogen (n) 31
Endometriosis recurrence (n) 17
Malignant transformation (n) 25
Mortality (n) 3
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Table II Case reports and series reporting the postmenopausal recurrence of endometriosis after HRT in women with a history of endometriosis.
Author, date
(# patients)
Patient
Age
(years)
Presenting symptoms
[ureter involvement]
Medical history and
menopause
HRT [duration] Diagnosis Treatment [follow-up: patient
status]
Skor et al.
(1977)
(N = 1)
48 Painless haematuria + palpable
bladder mass [No]
Endometriosis
Surgical menopause
Oestrogen-only HRT
Conjugated oestrogen tablets
[6 years]
Postmenopausal bladder
endometriosis
Discontinued oestrogens + initiated
Depo-Provera + surgery [1 year:
no complaints]
Stewart and
Ireland
(1977)
(N = 1)
65 Intermittent painless haematuria
[No]
Leiomyoma, no confirmed
history of endometriosis, but
speculated by authors
Unclear menopause
(underwent TAH + right SO at
age 59)
Oestrogen-only HRT
Oestrogen tablets [3 years]
Bladder endometriosis extending into
bowel
Surgery [6 weeks: cystoscopy
revealed normal appearing bladder
and bimanual examination was
normal]
Kapadia et al.
(1984)
(N = 1)
56 Painless haematuria; two
episodes of gross haematuria 10
days before admission [Yes]
Uterine leiomyomas, bilateral
endometriomas, right fallopian
tube endometriosis
Surgical menopause
Oestrogen-only HRT
Conjugated oestrogen tablets
[‘long term’]
Postmenopausal ureteral
endometriosis
Surgery [18 months: no complaints]
Ray et al.
(1985)
(N = 1)
64 Painless haematuria [Yes] Right ovarian endometriosis
Surgical menopause
Oestrogen-only HRT
Conjugated oestrogen tablets
[13 years]
Ureteral obstruction secondary to
adenomatous hyperplasia arising in
endometriosis
Surgery [Not specified]
Manyonda
et al. (1989)
(N = 2)
(1) 47
(2) 39
(1) Three day history of
vomiting and right iliac fossa
pain [Yes]
(2) Two day history of severe
left loin and left iliac fossa
pain [Yes]
(1) Bilateral ovarian
endometriosis
(2) Extensive endometriosis
Both surgical menopause
Oestrogen-only HRT
(1) Oestradiol implant,
ethinyloestradiol [5 years,
3 days 2 weeks prior to
presentation]
(2) Oestradiol implant [9 years]
(1) Large chocolate cyst (3 cm in
diameter) compressing ureter at
bifurcation of iliac vessel
(2) Chocolate cyst (3–4 cm in
diameter), endometriosis in the
cyst wall and end-stage
obstructive uropathy of the
kidney
(1) Surgery [2 years: no complaints,
on Danazol]
(2) Surgery [6 months: no
complaints, on Danazol]
Goh and Hall
(1992)
(N = 1)
54 5-month history of left iliac fossa
pain, especially during her
monthly withdrawal bleeding
[No]
Endometriosis suggested by
symptoms: primary infertility
and recurrent left iliac fossa
pain
Natural menopause
Combined HRT
Conjugated oestrogen tablets +
oral medroxyprogesterone
[1 year]
8 cm left ovarian endometrioma
adherent to sigmoid colon—uterus
had extensive endometrial deposits
on serosal surface
Surgery [2 years: no complaints, on
Premarin to treat menopausal
symptoms]
Joseph et al.
(1994)
(N = 1)
30 Recurrent haemoptysis and left-
sided haemothorax [No]
Extensive pelvic endometriosis,
pleural endometriosis
Surgical menopause
Combined HRT
Oestrogen and progesterone
[4 months]
Recurrent thoracic endometriosis Surgery [9 months: no complaints,
advised to delay HRT]
Taylor et al.
(1999)
(N = 3)
(1) 42
(2) 40
(3) 38
(1) Left abdominal pain and
vaginal bleeding [Yes]
(2) Severe lower abdominal pain
[No]
(3) Severe dyspareunia [No]
All had severe or extensive
endometriosis
All surgical menopause
Oestrogen-only HRT
All used oestradiol implants
(1) [3 years]
(2) [2 years]
(3) [2 years]
(1) Endometriotic mass in left pelvis
obstructing ureter
(2) Extensive pelvic endometriosis
(3) Endometriosis of vaginal vault
(1) Surgery [6 years: no complaints,
on continuous combined
hormone replacement]
(2) Surgery + discontinued
oestradiol implant [Not
specified]
(3) Surgery [Not specified, on
tibolone]
Badawy et al.
(2004)
(N = 2)
(1) 35
(2) 40
(1) Vaginal bleeding that
intensified and became
constant, severe cramping
[No]
(1) Severe chronic pelvic pain,
dyspareunia,
dysmenorrhoea, bilateral
ovarian endometriosis
Oestrogen-only HRT and
combined HRT
(1) Oestrogen patch followed by
‘various regiments of
Both—endocervical endometriosis (1) Surgery [Not specified]
(2) Surgery [Not specified, on ERT]
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Chahine et al., 2007). Two women were reported to have pelvic
masses (Skor et al., 1977; Mattar et al., 2008).
Sites of recurrence included: the genitourinary tract (n = 14), i.e.
bladder (Skor et al., 1977; Stewart and Ireland, 1977; Taylor et al.,
2005), ureter (Kapadia et al., 1984; Ray et al., 1985; Manyonda et al.,
1989; Taylor et al., 1999; Giarenis et al., 2009), ovary (Goh and Hall,
1992), cervix (Badawy et al., 2004), vagina (Taylor et al., 1999;
Giarenis et al., 2009); gastrointestinal organs (n = 4), i.e. the bowel
(Stewart and Ireland, 1977; Taylor et al., 2005; Mattar et al., 2008)
and rectum (Giarenis et al., 2009); and the pulmonary system (n = 2)
including the lung (Joseph et al., 1994) and bronchus (Chahine et al.,
2007). Mattar et al. (2008) reported an unusual presentation involving
an ovarian endometriotic cyst adherent to the small bowel with a
solitary vascular pedicle (Mattar et al., 2008). The authors hypothe-
sized spillage during previous surgery and reactivation with hormonal
therapy was responsible for this presentation.
Management of postmenopausal endometriosis recurrence
Management was tailored to location and extent of recurrence. All
cases, except for one (Chahine et al., 2007), required surgical excision
of endometriotic tissue. Some patients required additional medical
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Table III HRT dosages and regimens associated with
recurrent endometriosis in case reports and series.
HRT type Dosages and regimens associated with
recurrent postmenopausal endometriosis
(n = 17 patients)
Oestrogen-only 1. Premarin 1.25 mg/day (Skor et al., 1977)
2. Premarin (Kapadia et al., 1984)
3. Oestrogens 2.5 mg/day (Ray et al., 1985)
4. 2.5 mg oestrogen/day, but taking twice the
recommended dose (Stewart and Ireland, 1977)
5. Oestrogen patch 0.05 mg twice a week (Badawy
et al., 2004)
6. Conjugated oestrogen 1.25 mg/day (Giarenis
et al., 2009)
7. Oestradiol implant 100 mg 6 monthly for 5 years,
subsequent 2 years of taking no hormones, then
2 weeks before admission felt run down and took
three 10 μg tablets of ethinyloestradiol on
consecutive days (Manyonda et al., 1989)
8. 100 mg oestradiol annual hormone implants
(Manyonda et al., 1989)
9. Oestradiol implant (Taylor et al., 1999)
10. Oestradiol implant (Taylor et al., 1999)
11. Oestradiol implant (Taylor et al., 1999)
12. First oestradiol implant, then Evorel 50 patches
(Taylor et al., 2005)
Combined 13. Conjugated equine oestrogens 625 mcg,
norethisterone 150 mcg cyclically (Mattar et al.,
2008)
14. Premarin 0.625 mg daily and Provera 10 mg daily
for 12 days a month (Goh and Hall, 1992)
15. Oestrogen + progesterone (Joseph et al., 1994)
16. Oestrogen patch 0.05 mg weekly followed by
various regimens of oestrogen and progestogen
(Badawy et al., 2004)
17. Oestradiol and cyproterone (Chahine et al.,
2007)
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therapy involving Depo-Provera (Skor et al., 1977), Danazol (Manyonda
et al., 1989) and Tibolone (Taylor et al., 1999; Mattar et al., 2008).
Three patients resumed HRT after surgery (Goh and Hall, 1992; Taylor
et al., 1999; Badawy et al., 2004), two of whom were prescribed
oestrogen-only formulations (Goh and Hall, 1992; Badawy et al., 2004).
Outcomes were generally favourable, although reporting bias may
have contributed to this finding. All patients with reported follow-up
(range: immediate postoperative checks to 2 years post treatment)
experienced symptom regression with no relapses in the follow-up
period (Skor et al., 1977; Stewart and Ireland, 1977; Kapadia et al.,
1984; Manyonda et al., 1989; Goh and Hall, 1992; Joseph et al.,
1994; Taylor et al., 1999; Chahine et al., 2007; Giarenis et al., 2009).
Malignant transformation (25 patients)
Twenty case reports and series of malignant transformation of endo-
metriotic foci in postmenopausal women with a history of endometri-
osis on HRT were identified. This included a total of 25 patients
between the ages of 38 and 75 years old (mean: 56 years) (Table IV).
An additional study by Leiserowitz and colleagues (2003) (Leiserowitz
et al., 2003) detailing the malignant transformation of endometriosis in
six postmenopausal women on oestrogen-only HRT (mean duration:
23.4 years) is included in Table IV, but will be discussed separately.
Severity of prior endometriosis
About 13 patients had medical histories that noted endometriosis in
more than one site (Brooks and Wheeler, 1977; Duun et al., 1993;
Abu et al., 1997; Powell et al., 2001; Jones et al., 2002; Petersen
et al., 2002; Soliman and Evans, 2004; Milam et al., 2006; Noel et al.,
2006; Efthymiou, 2009; Karanjgaokar et al., 2009), and 13 patients
had histories of ovarian endometriosis (Brooks and Wheeler, 1977;
Duun et al., 1993; Abu et al., 1997; Jimenez et al., 2000; Powell et al.,
2001; Montamedi, 2002; Petersen et al., 2002; Soliman and Evans,
2004; Milam et al., 2006; Efthymiou, 2009; Karanjgaokar et al., 2009).
Some histories specified ‘severe endometriosis’ (n = 4) (Duun et al.,
1993; Abu et al., 1997; Taylor et al., 1999; Efthymiou, 2009), while
others reported ‘extensive endometriosis’ (n = 4) (Reimnitz et al.,
1988; Soliman and Evans, 2004; Noel et al., 2006). Some histories
included comorbidities such as leiomyomas (n = 6) (Brooks and
Wheeler, 1977; Reimnitz et al., 1988; Powell et al., 2001; Areia et al.,
2004; Soliman and Evans, 2004; Kawate et al., 2005) and adenomyosis
(n = 5) (Brooks and Wheeler, 1977; Abu et al., 1997; Powell et al.,
2001; Noel et al., 2006; Karanjgaokar et al., 2009). Patients typically
underwent surgical menopause (n = 22) (Brooks and Wheeler, 1977;
Reimnitz et al., 1988; Duun et al., 1993; Abu et al., 1997; Taylor et al.,
1999; Jimenez et al., 2000; Powell et al., 2001; Jones et al., 2002;
Montamedi, 2002; Petersen et al., 2002; Areia et al., 2004; Soliman
and Evans, 2004; Kawate et al., 2005; Milam et al., 2006; Noel et al.,
2006; Al-Talib et al., 2008; Efthymiou, 2009; Karanjgaokar et al., 2009).
Two additional patients underwent oophorectomy at ages 60 (Klug
et al., 1987) and 57 (Soliman and Evans, 2004) respectively; however,
it was unclear in these two cases whether the patients had already nat-
urally transitioned to menopause.
Menopausal hormonal preparations
HRT commonly consisted of unopposed oestrogens (n = 19) (Brooks
and Wheeler, 1977; Klug et al., 1987; Reimnitz et al., 1988;
Duun et al., 1993; Abu et al., 1997; Taylor et al., 1999; Jimenez et al.,
2000; Powell et al., 2001; Jones et al., 2002; Montamedi, 2002;
Petersen et al., 2002; Areia et al., 2004; Soliman and Evans, 2004;
Kawate et al., 2005; Milam et al., 2006; Noel et al., 2006; Al-Talib
et al., 2008; Karanjgaokar et al., 2009) for a median duration of
6.7 years (range 3–20 years). Conjugated equine oestrogens (Premarin
1.25mg/day or 0.625mg/day) were frequently mentioned (n = 8)
(Brooks and Wheeler, 1977; Klug et al., 1987; Reimnitz et al., 1988;
Jimenez et al., 2000; Powell et al., 2001; Soliman and Evans, 2004; Kawate
et al., 2005). Oestradiol implants were also implicated (n = 4) (Abu et al.,
1997; Taylor et al., 1999; Jones et al., 2002; Karanjgaokar et al., 2009), as
well as oestrogen injections (n = 1) (Duun et al., 1993). One interesting
case of ureteral malignant mullerian carcinosarcoma in a 75-year-old
woman was associated with 5 years of taking a phytoestrogen sup-
plement (highly concentrated soy isoflavone) (Noel et al., 2006).
Of note, two incidences of malignancy were reported in women
who had discontinued HRT several years before presentation
(Karanjgaokar et al., 2009). In a case series of women over 55 years
old, one woman used oestrogen implants (50–100mg every 6 months)
for 14 years post hysterectomy. She had stopped this regimen for
8 years before presenting with malignancies (adenosarcoma and endo-
metrioid adenocarcinoma). Another patient in this series was on a regi-
men of 50mg oestradiol and 50mg testosterone implants for 12 years
post surgical menopause. She was not on any form of HRT for 4 years
before presenting with an endometrioid adenocarcinoma.
Presentation
Patients in these case reports/series presented with symptoms
related to the site, extent, and type of malignancy. Vaginal bleeding
was common (n = 7) (Klug et al., 1987; Reimnitz et al., 1988;
Abu et al., 1997; Areia et al., 2004; Soliman and Evans, 2004;
Karanjgaokar et al., 2009; Suraweera et al., 2012), as was pain in the
abdomen/pelvis/buttock (n = 11) (Brooks and Wheeler, 1977;
Powell et al., 2001; Montamedi, 2002; Petersen et al., 2002; Milam
et al., 2006; Noel et al., 2006; Chung et al., 2008; Karanjgaokar
et al., 2009). Masses were also frequently reported (n = 9)
(Duun et al., 1993; Petersen et al., 2002; Soliman and Evans,
2004; Kawate et al., 2005; Milam et al., 2006; Al-Talib et al.,
2008; Chung et al., 2008). Less frequent presentations included
weight loss (n = 3) (Montamedi, 2002; Chung et al., 2008; Efthymiou,
2009), constipation (n = 3) (Brooks and Wheeler, 1977; Chung et al.,
2008; Efthymiou, 2009) and flank pain (n = 3) (Reimnitz et al., 1988;
Jimenez et al., 2000).
Malignant transformation and management
Malignant transformation of endometriotic foci was commonly diag-
nosed using Sampson’s (Sampson, 1925) and Scott’s (Scott, 1953) cri-
teria. Endometrioid adenocarcinoma was by far the most commonly
diagnosed HRT-associated malignancy in patients with a history of
endometriosis (n = 18) (Klug et al., 1987; Reimnitz et al., 1988; Duun
et al., 1993; Abu et al., 1997; Taylor et al., 1999; Jones et al., 2002;
Montamedi, 2002; Petersen et al., 2002; Areia et al., 2004; Soliman
and Evans, 2004; Kawate et al., 2005; Al-Talib et al., 2008; Chung
et al., 2008; Efthymiou, 2009; Karanjgaokar et al., 2009). Other histo-
logical types included adenosarcoma (n = 2) (Milam et al., 2006;
Karanjgaokar et al., 2009), clear cell carcinoma (n = 1) (Brooks and
Wheeler, 1977), mullerian carcinosarcoma (n = 1) (Noel et al., 2006),
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Table IV Case reports and series reporting malignant transformation of endometriotic foci after HRT in women with a history of endometriosis.
Author,
date (#
patients)
Patient
age
(years)
Presenting symptoms
[ureter involvement]
Medical history and menopause HRT [duration] Diagnosis Treatment [follow-up: patient
status]
Brooks and
Wheeler
(1977)
(N = 1)
48 Mild right-sided lower
abdominal pain, urinary
frequency, constipation for 2
months [No]
Pelvic endometriosis, left ovarian
endometriosis, adenomyosis,
leiomyomas
Surgical menopause
Oestrogen-only HRT
Conjugated oestrogen tablets
[4 years]
Clear cell carcinoma arising in
endometriosis of the
retroperitoneum
Surgery + radiation [22 months: no
evidence of disease]
Klug et al.
(1987)
(N = 1)
66 Light vaginal bleeding [No] Genital endometriosis
Natural menopause + TAH/BSO 6
years before presentation
Oestrogen-only HRT
Conjugated oestrogen tablets
[12 years]
Endometrioid carcinoma arising in
an endometriotic lesion of the
cul-de-sac
Surgery [Unclear]
Reimnitz
et al. (1988)
(N = 2)
(1) 58
(2) 47
(1) Vaginal bleeding and left
flank pain [Yes]
(2) Nausea, vomiting, fever
and flank pain [Yes]
(1) Extensive endometriosis and
leiomyomata
Surgical menopause
(2) Extensive pelvic endometriosis
Surgical menopause
Both oestrogen-only HRT
Both conjugated oestrogen tablets
(1) [12 years]
(2) [4 years]
(1) Extra-ovarian endometrioid
carcinoma arising in foci of
endometriosis
(2) Adenocarcinoma +
adenosquamous carcinoma
arising in foci of endometriosis
3 months later
(1) Surgery + progestin therapy
[60 months: no evidence of
disease]
(2) Surgery + progestin therapy +
radiation + chemotherapy [11
months: patient deceased]
Duun et al.
(1993)
(N = 1)
62 Pelvic mass [No] Severe endometriosis (both ovaries
and extensions deep into the
rectovaginal septum)
Surgical menopause
Oestrogen-only HRT
Intramuscular oestrogen injections
[20 years]
Endometrioid adenocarcioma
(extraluminal rectosigmoid
tumour 10 cm in diameter and
closely adherent to the bladder)
Surgery + radiation [6 weeks:
patient deceased]
Abu et al.
(1997)
(N = 1)
38 Intermittent vaginal bleeding
of 8 weeks duration,
ulcerated area over vaginal
vault, polyp-like lesion on
vaginal vault found 4 weeks
later [No]
Severe endometriosis involving both
ovaries, adenomyosis of the uterus,
chronic cervicitis
Surgical menopause
Oestrogen-only and combined
HRT
Ethinyloestradiol tablets [Not
specified]
Levonorgestrel/ethinyloestradiol
tablets [Not specified]
Oestradiol implants [Not
specified]
Endometrial adenocarcinoma
arising from an endometriotic
focus
Neoadjuvant progestin therapy +
surgery + radiation [Not specified]
Taylor et al.
(1999)
(N = 1)
42 Massive ascites, 6L drained
[No]
Severe endometriosis
Surgical menopause
Oestrogen-only HRT
Oestradiol implants [7 years]
Endometroid adenocarcinoma Surgery + chemotherapy [24
months: no evidence of disease]
Jimenez et al.
(2000)
(N = 1)
48 Right flank discomfort [Yes] Endometriotic ovarian cyst
Surgical menopause
Oestrogen-only HRT
Conjugated oestrogen tablets
[5 years]
Adenosquamous endometrioid
carcinoma arising from
disseminated pelvic
endometriosis
Surgery [Not specified]
Powell et al.
(2001)
(N = 1)
56 Lower abdominal pain,
dyspareunia, pain with bowel
movements, hirsutism [Yes]
Extensive pelvic adhesions, peritoneal
endometriosis, left ovarian
endometrioma, adenomyosis,
multiple leiomyomas
Surgical menopause
Oestrogen-only HRT and
combined HRT
Conjugated oestrogen tablets
[10 years]
Medroxyprogesterone tablets
[3 years]
Androgen-producing
endometrioid tumour of low
malignant potential (borderline
tumour) arising in endometriosis
in the rectovaginal septum
Surgery + chemotherapy +
progestin therapy [9 months: no
evidence of disease]
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Table IV Continued
Author,
date (#
patients)
Patient
age
(years)
Presenting symptoms
[ureter involvement]
Medical history and menopause HRT [duration] Diagnosis Treatment [follow-up: patient
status]
Jones et al.
(2002)
(N = 1)
52 Rectal bleeding and polyp
arising from sigmoid colon
[Yes]
Deeply infiltrating rectovaginal
endometriosis
Surgical menopause
Oestrogen-only HRT
Oestradiol implants [12 years]
Well-differentiated endometrial
adenocarcinoma arising from
endometriosis of the
rectosigmoid colon
Surgery [9 months: no evidence of
disease]
Montamedi
(2002)
(N = 1)
57 Right lower-quadrant pain,
recurrent macroscopic
haematuria and weight loss of
8 kg in 3 months [Yes]
Uterine fibroids and right-sided
endometrioma
Surgical menopause (left ovary and
fallopian tube left intact)
Oestrogen-only HRT
Oestradiol [‘many years’]
Tubulopapillary endometrioid
adenocarcinoma involving blood
vessels
Surgery + radiation [18 months: no
evidence of disease]
Petersen
et al. (2002)
(N = 2)
(1) 61
(2) 57
(1) Diarrhoea, right buttock
pain, rectal mass [No]
(2) Lower abdominal pain,
rectal mass [No]
(1) Endometriosis
Surgical menopause
(2) Endometriotic foci on uterus,
haemorrhagic endometriotic
ovarian cyst
Surgical menopause
(1) Oestrogen-only HRT [5 years]
(2) HRT [8 years]
(1) Poorly differentiated
endometrioid
adenocarcinoma of the large
intestine arising in colorectal
endometriosis
(2) Variably differentiated
endometrioid
adenocarcinoma
(1) Surgery [28 months: no
evidence of disease]
(2) Surgery [18 months: no
evidence of disease]
Leiserowitz
et al. (2003)a
(N = 10)
54.9
(mean)
Not reported Not reported
Surgical menopause (n = 8)
Oestrogen-only HRT (n = 6)
[23.4 years (mean), 10–32 years
(range)]
Endometrioid (n = 5)
Adenosquamous (n = 2)
Papillary adenocarcinoma (n = 1)
Adenocarcinoma not otherwise
specified (n = 2)
Surgery, chemotherapy, radiation
[26 months (mean): 70% survival]
Soliman and
Evans (2004)
(N = 2)
(1) 60
(2) 51
(1) Heavy, painless vaginal
bleeding, palpable fixed
mass, polypoid necrotic
lesion [Yes]
(2) Painless mass in the right
side of abdomen and
several episodes of vaginal
bleeding [Yes]
1) Pelvic endometriosis,
microinvasive squamous carcinoma
of the cervix, leiomyoma
Menopause not specified (surgical
menopause at age 57)
2) Extensive endometriosis involving
the uterosacral ligaments,
endometriotic right ovarian cyst
Surgical menopause (left ovary and
Fallopian tube left intact)
1) Oestrogen-only HRT
Conjugated equine oestrogen
tablets [3 years]
2) Combined HRT
Oestrogen and testosterone
implants [10 years]
(1) Moderately differentiated
endometrial adenocarcinoma
(2) Endometrioid
adenocarcinoma arising in an
endometriotic cyst within the
vaginal vault
(1) Surgery and radiation
[48 months: no evidence
of disease]
(2) Surgery [24 months: no further
tumour growth]
Areia et al.
(2004)
(N = 1)
53 Abnormal vaginal bleeding for
2 months [Yes]
Leiomyomata, endometrioid foci
especially in Fallopian tubes
Surgical menopause
Oestrogen-only HRT
Oestradiol [6 years]
Endometrioid adenocarcinoma
affecting the vagina, bladder and
rectum
Surgery + chemotherapy [6
months: no evidence of disease]
Kawate et al.
(2005)
(N = 1)
62 Abdominal mass [No] Infiltrating pelvic endometriosis,
leiomyoma
Surgical menopause
Oestrogen-only HRT
Conjugated oestrogen tablets
[14 years]
Endometrioid adenocarcinoma
arising from endometriosis of the
mesocolon
Surgery + chemotherapy [28
months: no evidence of disease]
Noel et al.
(2006)
(N = 1)
75 Chronic abdominal pain for
2 months, left pyelonephritis
[Yes]
Extensive endometriosis and
adenomyosis
Surgical menopause
Oestrogen-only HRT
Super concentrated phytoestrogen
supplements [5 years]
Ureteral malignant mullerian
carcinosarcoma in a context of
florid endometriosis
Surgery + aromatase inhibitor [3
months: no evidence of disease]
Milam et al.
(2006)
(N = 1)
47 Persistent and enlarging right
groin mass, right lower-
quadrant tenderness [No]
Recurrent endometriosis, left and
right endometriomas
Surgical menopause
Oestrogen-only HRT
Oestrogen tablets [16 years]
Adenosarcoma arising in
endometriosis
Surgery [12 months: no evidence
of disease]
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Al-Talib et al.
(2008)
(N = 1)
68 Left-sided pelvic mass,
shortness of breath [No]
Endometriosis and multiple large
fibroids
Surgical menopause
Oestrogen-only HRT [13 years] Metastatic endometrioid
adenocarcinoma
Chemotherapy [24 months: patient
is alive and well]
Chung et al.
(2008)
(N = 1)
66 Abdominal/pelvic pain and
mass, alteration of general
state, 10 kg weight loss,
constipation, dysuria [Yes]
Never had endometriosis-specified
pain, but unclear whether patient had
endometriosis
Natural menopause
Combined HRT
Oestradiol and
medroxyprogesterone acetate
[11 years]
Extragenital endometrioid
carcinoma in the vesico-uterine
pouch arising from endometriosis
Surgery + chemotherapy +
radiation [8 months: patient
deceased]
Efthymiou
(2009)
(N = 1)
59 8-week history of
constipation, tenesmus, 7 kg
weight loss [No]
Severe ovarian endometriosis and in
floor of pelvis
Surgical menopause
Combined HRT
Oestradiol and testosterone
implant [13 years]
Well-demarcated, cystic,
endometrioid adenocarcinoma
(endometriosis-associated
intestinal tumour)
Surgery [Not specified]
Karanjgaokar
et al. (2009)
(N = 3)
(1) 60
(2) 56
(3) 55
(1) Intermittent right-sided
abdominal pain for 4 years
[Yes]
(2) Recent onset of
discomfort in her right
iliac fossa [No]
(3) Cramp-like discomfort in
the abdomen and thighs
and postmenopausal
bleeding [No]
1) Ovarian endometriosis and
adenomyosis
Surgical menopause
2) Widespread endometriosis in the
ovary, uterine serosa and bowel
Surgical menopause
3) Endometriosis and left ovarian
endometrioma
Surgical menopause
1) Oestrogen-only HRT
Oestrogen implants [14 years,
discontinued 8 years before
presentation]
2) Combined HRT
Oestradiol and testosterone
implants [12 years, discontinued
4 years before presentation]
3) Combined HRT
Oestrogen and testosterone
implants [9 years]
(1) Adenosarcoma with
heterologous
leiomyosarcomatous element
and moderately differentiated
endometrioid
adenocarcinoma
(2) Endometrioid
adenocarcinoma
(3) High grade endometrial
stromal sarcoma arising in
residual foci of endometriosis
and infiltrating the bowel
(1) Surgery + aromatase inhibitor +
chemotherapy
(2) Surgery + chemotherapy
(3) Surgery + chemotherapy
[All cases were still being treated
at the time of publication]
TAH/BSO, total abdominal hysterectomy and bilateral salpingo-oophorectomy.
aArticle describes a total of 27 women with endometriosis-related malignancy; however, it is unclear how many of these women were postmenopausal. A subgroup of women with extra-ovarian disease (n = 10) included eight women
with a history of hysterectomy and BSO, and one further woman who was taking unopposed oestrogens (therefore was presumably menopausal). For the purposes of this analysis, only these 10 women are described.
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endometrial stromal sarcoma (n = 1) (Karanjgaokar et al., 2009) and
an androgen-producing endometrioid borderline tumour (n = 1)
(Powell et al., 2001). One interesting study reported an adenocarcin-
oma followed by an adenosquamous carcinoma arising in endometrio-
tic foci 3 months later (Reimnitz et al., 1988).
Treatments varied based on histological type, grade and stage of
the tumour. In only one case it was decided to forego surgical man-
agement and treat solely with chemotherapy (Al-Talib et al., 2008).
In this case, the decision to initiate chemotherapy instead of surgery
was based on her previous surgical history (two ileostomies) and
poor prognosis due to advanced disease.
Adjuvant or neoadjuvant treatments in the form of chemotherapy
(n = 9) (Reimnitz et al., 1988; Taylor et al., 1999; Powell et al., 2001;
Areia et al., 2004; Kawate et al., 2005; Chung et al., 2008;
Karanjgaokar et al., 2009), radiation (n = 7) (Brooks and Wheeler,
1977; Reimnitz et al., 1988; Duun et al., 1993; Abu et al., 1997;
Montamedi, 2002; Soliman and Evans, 2004; Chung et al., 2008) or
progestin therapy (n = 4) (Reimnitz et al., 1988; Abu et al., 1997;
Powell et al., 2001) were frequently initiated. Mean follow-up was
19.4 months (range: 6 weeks to 5 years). Outcomes were generally
favourable with no evidence of disease in 13 patients at follow-up
(Brooks and Wheeler, 1977; Reimnitz et al., 1988; Taylor et al.,
1999; Powell et al., 2001; Jones et al., 2002; Montamedi, 2002;
Petersen et al., 2002; Areia et al., 2004; Soliman and Evans, 2004;
Kawate et al., 2005; Milam et al., 2006; Noel et al., 2006). The
patient treated solely with chemotherapy was alive and well at 2
years after presentation (Al-Talib et al., 2008).
Mortality
Although the majority of patients responded to treatment and were
cured of their malignancy, three of the 25 patients diagnosed with an
endometriosis-associated malignancy died as a result of their disease
(Reimnitz et al., 1988; Duun et al., 1993; Chung et al., 2008).
Reimnitz et al. (1988) reported the case of a 47-year-old woman
with a history of extensive pelvic endometriosis. She was on conju-
gated oestrogens (Premarin) 0.625 mg for 5 days every week for 4
years. She was initially diagnosed with a grade two adenocarcinoma
arising from an endometriotic focus and obstructing the left ureter.
Subsequently she was also diagnosed with moderately differentiated
adenosquamous carcinoma arising from endometriotic foci. The
patient was treated with cisplatinum and cyclophosphamide chemo-
therapy, but died after 11 months. In the case reported by Duun
et al. (1993), the patient was a 62-year-old woman with a history of
severe endometriosis involving both ovaries and the rectovaginal sep-
tum. She had received intramuscular oestrogen injections for 20 years
following a hysterectomy and bilateral oophorectomy. After 3 years
with no treatment, she resumed another hormone substitution regi-
men (not specified) for hot flushes. Within a year of commencing this
hormonal substitution, the patient presented with a pelvic mass diag-
nosed as endometrioid adenocarcinoma. About 6 weeks after
tumour excision, recurrence was diagnosed and the patient died des-
pite radiotherapy. Chung et al. (2008) reported the case of a 66-
year-old woman who presented with abdominal/pelvic pain and
mass, alteration of general state, 10 kg weight loss, constipation and
dysuria. She had used combined HRT (oestradiol and medroxypro-
gesterone acetate) for 11 years. After being diagnosed with extrage-
nital endometrioid carcinoma in the vesico-uterine pouch arising from
endometriosis, she was treated with surgery, chemotherapy and radi-
ation. The patient was deceased 8 months later.
One unique case series by Leiserowitz et al. (2003) identified by
our search reported on larger numbers of women and thus is pre-
sented separately. They describe the management of 27 women with
endometriosis-related malignancy, identified during a 7-year period
(by their presentation to one of the authors, and review of pathology
records). The authors include all women with endometriosis-related
malignancy, rather than exclusively postmenopausal women. However,
it is clear from the article that a number of participants were postme-
nopausal. In particular, 10 women were identified with extragonadal
(non-ovarian) malignancy, and 9 of these were clearly menopausal
(with either a medical history of hysterectomy/BSO, or reported as
using HRT). Of these 10 women, their malignancies were histologically
described as endometrioid (n = 5), adenosquamous (n = 2), papillary
adenocarcinoma (n = 1) or adenocarcinomas not otherwise specified
(n = 2). Within this group, six women had taken unopposed oestrogen
therapy for a mean duration of 23.4 years (range 10–32 years). The
authors therefore suggest that unopposed oestrogen use could be a
risk factor for endometriosis-associated malignancy, especially of non-
ovarian location. Treatments included surgery, chemotherapy and radi-
ation with a 70% reported survival at follow-up (mean: 26.3 months).
Observational studies and clinical trials
(6 studies)
Only six observational studies and clinical trials were identified by our
search, highlighting the paucity of higher-level evidence in this area.
These studies aimed to cover a variety of clinical questions, and the
evidence for these is summarized below and in Table V. All assessed
recurrence of endometriosis as their primary outcome.
Should HRT be given to women with
previous endometriosis?
Given the concerns of possible disease reactivation or malignant
transformation of endometriotic foci, it is reasonable to consider
whether treatment with HRT is justifiable in this group of women.
However, in a field dominated by case reports and series, it is chal-
lenging to obtain information on risk. Our search identified a single
RCT and two cohort studies that give some insight regarding the risk
of HRT in this cohort of women. All three studies were assessed as
very low quality by GRADE criteria (Guyatt et al., 2011).
The only RCT in this area was a single centre study from Spain,
including a total of 172 women (Matorras et al., 2002). All partici-
pants had a history of endometriosis and underwent BSO. Women
were randomly allocated to treatment with combined HRT (50 μg
oestradiol daily administered via patches and oral micronized proges-
terone for 14 days out of every 30 days) or no treatment.
Participants were aware of their treatment allocation, although the
clinician assessing them was not. In the treatment group, HRT was
started 4 weeks following surgery. All women were followed up
every 6 months with a clinical review, vaginal ultrasound and hor-
mone measurements. Recurrence of endometriosis was identified
either through histological confirmation, or by clinical findings (pelvic
pain and/or pelvic mass) in association with pelvic ultrasound images
suggestive of endometriosis. The overall absolute recurrence rate for
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Table V Quality assessment of observational and clinical trials assessing risk of endometriosis recurrence after HRT.
Quality assessment No of patients Effect Evidence
quality
Studies Study
design
Risk of
bias
Inconsistency Indirectness Imprecision Other
considerations
Intervention Control Relative
(95% CI)
Comparison of HRT with no HRT HRT No treatment
Matorras et al. (2002) Randomized
trial
Seriousa Not serious Not serious Very seriousb None 4/115 (3.5%) 0/57 (0.0%) RR 4.50
(0.25 to 82.17)c
⨁◯◯◯
VERY LOW
Rattanachaiyanont
et al. (2003)
Observational
study
Very
seriousd
Not serious Not serious Very seriousb None 4/90 (4.4%) 0/17 (0.0%) RR 1.78
(0.10 to 31.64)c
⨁◯◯◯
VERY LOW
Acien et al. (2013) Observational
study
Seriouse Not serious Not serious Not
applicablef
None 0/11 (0%) 0/8 (0%) Not calculableg ⨁◯◯◯
VERY LOW
Comparison of delayed HRT with immediate HRT Delayed HRT Immediate HRT
Hickman et al. (1998) Observational
study
Not
serious
Not serious Not serious Not serious None (>6 weeks from
surgery)
7/35 (20.0%)
(≤6 weeks from surgery)
4/60 (6.7%)
HR 5.74
(1.31 to 25.23)h
⨁⨁◯◯
LOW
Arumugam and
Damodaran (1998)
Observational
study
Very
seriousi
Not serious Not serious Not
applicable
None (5 months from
surgery)
0/8 (0%)
(3 months from surgery)
0/5 (0%)
Not calculableg ⨁◯◯◯
VERY LOW
Comparison of HRT with tibolone HRT Tibolone
Fedele et al. (1999) Randomized
trial
Seriousj Not serious Not serious Very seriousb None 4/10 (40.0%) 1/11 (9.1%) RR 4.40
(0.59 to 33.07)c
⨁◯◯◯
VERY LOW
Comparison of oestrogen-only HRT with combined HRT Oestrogen-
only HRT
Combined HRT
(continuous and cyclical)
Rattanachaiyanont
et al. (2003)
Observational
study
Very
seriousd
Not serious Not serious Very seriousb None 4/50 (8.0%) 0/40 (0.0%) RR 7.24
(0.40 to 130.54)c
⨁◯◯◯
VERY LOW
CI, confidence interval; HR, hazard ratio; HRT, hormone replacement therapy; RR, risk ratio.
aHigh risk of performance bias—single blinded study, with physician unaware of treatment allocation, but with access to hormone results (which would have indicated treatment with HRT or not). High risk of detection bias, as assess-
ment for recurrence was only carried out if the clinician felt this was warranted, which may have been influenced by the participant (who was not blind to treatment allocation).
bVery wide CI for RR.
cRR calculated by the authors using Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
dHigh risk of selection bias as unclear why women were allocated to different HRT regimens (or no HRT). High risk of detection bias, as researchers would have been aware of the woman’s HRT status when assessing presence of recur-
rence (by reviewing medical records).
eRisk of detection bias, as criteria for designating recurrence are not clearly stated.
fNot applicable as odds ratio and CI cannot be calculated.
gNo events in either group, therefore odds ratio not calculable.
hHR adjusted for stage of endometriosis, age at time of hysterectomy and postoperative adjunct medroxyprogesterone therapy.
iHigh risk of selection bias (unclear why some women started HRT after 3 months and some after 5 months), and high risk of detection bias (recurrence was only based on CA 125 levels).
jNo description of blinding for the trial, and no scoring system is reported for pain, therefore risk of detection bias.
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endometriosis in this study was low at 2.3% (4/172). However, all
women who experienced recurrence of endometriosis had been
assigned to the HRT treatment arm (recurrence in 3.5% (4/115) of
women compared to 0% (0/57) of women in the no treatment arm).
The authors also suggested that the presence of residual endometrial
tissue may be a possible risk factor for disease recurrence. In this
cohort, the recurrence rate was 22.2% in women who had either a
subtotal hysterectomy or BSO alone (2 out of 9 women). In contrast,
the rate was only 1.9% (2 out of 106 women) in those who had total
hysterectomy and BSO. The authors further suggest that a greater
burden of disease may increase the risk of recurrence, as shown by
an increased recurrence risk for women who had peritoneal involve-
ment of greater than 3 cm, and a non-significant trend to increased
recurrence with more advanced stages of endometriosis. The authors
rightly noted that their study was underpowered to detect a statistic-
ally significant change in recurrence rates between the two groups of
women. However, the study raises interesting possibilities for further
research into the effect of disease stage and extent on recurrence
rates.
One observational study included women who took postoperative
HRT (of different regimens) and those who did not (Rattanachaiyanont
et al., 2003). In this retrospective, single centre cohort, the authors
identified 107 women who had undergone hysterectomy and BSO for
treatment of endometriosis. Women were treated with a variety of
HRT regimens (total n = 90, taking unopposed oestrogen, continuous
combined HRT, or cyclic HRT) or no treatment (n = 17). Recurrence
was only identified in four women and all were receiving HRT, specific-
ally unopposed oestrogen therapy. Three women had recurrent pain,
and one woman had a vaginal nodule, confirmed as endometriosis on
histology.
One further observational study reported on outcomes of women
with deep infiltrating endometriosis and colorectal or rectovaginal dis-
ease, who underwent surgery without bowel resection (Acien et al.,
2013). This retrospective comparative cohort study was conducted
in Spain and included women who were operated on at one of two
hospitals. Of 42 patients, 19 had a hysterectomy and BSO, whilst the
remainder had conservative surgery. Of the 19 women who under-
went surgical menopause, 11 were subsequently treated with HRT,
comprising 1–2 years of combined oestrogen/progesterone, followed
by low dose oestrogen-only HRT or tibolone, continued indefinitely.
The remaining 8 women did not receive HRT. The mean follow-up
was 4.3 years (standard deviation 4.5, range 1–18). During this time,
no women from either group were diagnosed with recurrence of
endometriosis.
Should HRT be given immediately following
surgical menopause?
Further questions arise for women who undergo surgical menopause.
If small deposits of endometriotic tissue remain following surgery, these
may be triggered to proliferate by exogenous oestrogens given as HRT
and increase the risk of recurrence or malignant transformation.
Therefore, there may be a theoretical benefit in delaying the start of
HRT, by allowing time for residual endometriotic tissue to regress
before commencing exogenous oestrogen. Two retrieved articles, a
retrospective cohort study (Hickman et al., 1998) (GRADE: low
quality) and non-comparative cohort (Arumugam and Damodaran,
1998) (GRADE: very low quality), attempted to investigate this
question.
The retrospective cohort study (Hickman et al., 1998) included
women who underwent TAH with BSO, identified from the medical
records of a single institution during a period of 12 years
(1979–1991). Two groups of women were identified: those who
commenced HRT within 6 weeks of their surgery (n = 60) and those
who delayed starting HRT for at least 6 weeks (n = 35, mean time to
starting HRT 71.1 weeks, range 7–520 weeks). Women who did not
receive HRT were excluded. Information on symptom recurrence
was obtained through the medical records or telephone follow-up,
but a precise definition of recurrence was not reported. The mean
duration of follow-up was 4.5 years. In unadjusted analyses, 4/60
(6.7%) women who began HRT immediately had recurrent pain,
compared to 7/35 (20%) women who began HRT later on. Of note,
in their adjusted analyses, in which endometriosis stage, age and post-
operative adjunct medroxyprogesterone therapy were considered,
starting oestrogen-replacement therapy (ERT) more than 6 weeks
after surgical menopause had a hazard ratio of 5.7 for pain recurrence
(95% CI; 1.3, 25.2). The authors therefore conclude that there is no
increase in the risk of recurrence for women who commenced ERT
immediately, as compared to those who delayed treatment.
A non-comparative cohort study (Arumugam and Damodaran,
1998) prospectively followed 13 women at one institution in Malaysia
undergoing TAH and BSO for moderate or severe endometriosis.
Patients were premenopausal at recruitment and had their endome-
triotic activity assessed by blood CA 125 levels taken pre-operatively
and post-operatively (monthly). Eight patients received conjugated
oestrogens in the form of Premarin (oral dose of 0.625 mg/day)
starting 5 months post surgery, and five patients received oestrogens
3 months post surgery. Preoperative CA 125 levels were high in all
13 patients and declined to normal post surgery. Levels did not rise
during the 6-month follow-up period and patients remained well and
asymptomatic.
What menopausal treatments are most
appropriate for women with previous
endometriosis?
If a woman with a history of endometriosis does decide to opt for
HRT, then the next decision must be to choose the most suitable
preparation. Again, there is limited high-quality evidence on which to
base this decision. Two studies, retrieved by our search, provide
some insight into this question. The first was a RCT (Fedele et al.,
1999) comparing HRT using transdermal oestradiol with tibolone,
and the second was an observational study (Rattanachaiyanont et al.,
2003) comparing oestrogen-only HRT with combined HRT. Both
were assessed as very low quality using the GRADE system.
The RCT (Fedele et al., 1999) compared HRT (n = 10, transder-
mal oestradiol 50 mg twice weekly plus cyclic medroxyprogesterone
acetate 10 mg daily for women with a uterus) and tibolone (n = 11,
2.5 mg orally once a day) in women with residual endometriosis after
bilateral oophorectomy. Patients were randomized into one of the
two treatment groups and followed for 1 year. Four patients in the
oestradiol group experienced moderate pelvic pain during treatment
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compared to only one patient in the tibolone group. Furthermore,
one patient in the HRT group discontinued treatment at 8 months
due to the development of dyspareunia and post-coital bleeding from
a vaginal mucosal endometriotic deposit. The authors concluded that
tibolone may be a safer alternative for postmenopausal women with
residual endometriosis, although note that their trial was very small.
The observational cohort study (Rattanachaiyanont et al., 2003)
attempted to compare various HRT regimens in women who had
undergone hysterectomy and BSO for endometriosis. The majority of
women (n = 50) were treated with unopposed oral oestrogen.
Others were prescribed either continuous combined HRT (n = 24)
or cyclical HRT (n = 16). Women received either conjugated equine
oestrogens or oestradiol. Finally, a small group of women received
no HRT (n = 17) and were viewed as controls. Women were fol-
lowed up for a mean duration of 3.5 years (range 0.5–18 years).
Although there were no statistically significant differences between
the groups, the only episodes of recurrence (n = 4) were found in
the oestrogen-only group. One woman who suffered with recurrent
symptoms whilst taking oestrogen-only HRT also had relief of her
symptoms when changing to a combined preparation. The authors
conclude that HRT, particularly combined oestrogen and progestin
regimens, is safe for postmenopausal women with underlying
endometriosis.
Discussion
In response to concerns regarding an increased risk of breast cancer
raised by the Women’s Health Initiative (Rossouw et al., 2002) and
the Million Women Study (Collaborators, 2003), HRT usage substan-
tially decreased (Hersh et al., 2004). Nevertheless, millions of women
continue to rely on hormonal preparations for menopausal symptom
relief and HRT remains the most effective treatment for menopausal
vasomotor symptoms and vulvar and vaginal atrophy (Schmidt, 2012).
However, amongst women with a history of endometriosis, HRT may
entail additional risks, and to date there are no high-quality evidence-
based guidelines to guide clinical decisions.
The articles described here provide insight into the management of
menopausal symptoms amongst women with a prior history of endo-
metriosis. The case reports and series included in our review, while
limited in their usefulness in assessing prevalence, indicate that recur-
rence of endometriosis and malignant transformations can occur in
postmenopausal women. Observational studies and clinical trials have
further investigated the contingent risks of different forms and timing
of HRT treatments.
Recurrence
Endometriosis is not exclusively a premenopausal disease. About 13
case reports and series found 17 cases of recurrent endometriosis in
postmenopausal women taking some form of HRT. These cases
included women who underwent natural and surgical menopause;
however, the vast majority underwent surgical menopause, perhaps
indicating more severe premenopausal disease. Similarly, Vignali and
colleagues (2005) reported substantial 5-year endometriosis recur-
rence rates, albeit amongst premenopausal women, of 43.5% (pain)
and 28% (clinical disease) for women treated with conservative
surgery (preservation of the uterus and at least one ovary) (Vignali
et al., 2005).
In the case reports, symptoms of postmenopausal endometriosis
were similar to those reported in premenopausal endometriosis
(Mounsey et al., 2006): abnormal bleeding and pain. There are few
papers describing the presentation of chronic pelvic pain (CPP) in
postmenopausal women specifically. From clinical experience, symp-
toms are not cyclical unless a cyclical HRT preparation is used; how-
ever, pain associated with bowel and bladder function is common in
postmenopausal women with CPP. Dyspareunia, especially superfi-
cially, may be associated with atrophic tissues but may also present in
women using HRT with well-oestrogenized tissues. Deep dyspar-
eunia, the more pathognomonic form of painful intercourse asso-
ciated with endometriosis, is rarely described. Future research should
investigate the prevalence of this symptom and whether and to what
extent dyspareunia (superficial or deep) may contribute to postme-
nopausal sexual behaviour. Perhaps the most important difference in
clinical practice, however, is the need to investigate new onset pelvic
pain in a postmenopausal woman, whilst guidance on the manage-
ment of CPP in reproductive age women emphasizes the need to
avoid over-investigation and thus over-medicalization of the symptom
when no underlying cause has previously been found (Home Page.
Map of Medicine Web site. http://www.mapofmedicine.com/.
[Accessed January 2017]). Findings from this review would suggest
that investigation is needed when a postmenopausal woman is known
to have had a previous diagnosis of endometriosis due to the added
risk of malignant transformation.
The genitourinary system was the most common site of presenta-
tion, with many reports involving the ureter. This may represent the
bias of case reports towards documenting more severe cases. Ureter
involvement is a serious complication of endometriosis, capable of
causing hydronephrosis and renal failure (Choi et al., 2015). It has
been suggested that most cases of ureteral endometriosis in postme-
nopausal women are actually a result of delayed presentation with
onset prior to menopause (Yohannes, 2003). However, due to a lack
of clinically relevant biomarkers and sufficiently specific imaging tech-
niques, the onset of endometriosis remains unclear (May et al., 2010;
Dunselman et al., 2014).
Prognosis was generally favourable after excision of endometriotic
tissue. Randomized controlled trials corroborate these findings,
reporting decreased pain and symptoms after laparoscopic surgery
for endometriosis, although these trials did not specifically investigate
ureteric surgery (Duffy et al., 2014).
In three observational studies and one randomized clinical trial
(Arumugam and Damodaran, 1998; Matorras et al., 2002;
Rattanachaiyanont et al., 2003; Acien et al., 2013), there appeared to
be a small association between HRT and endometriosis recurrence,
but there were no statistically significant differences between treat-
ment and control groups. The current literature assessing risks of
HRT in women with a history of endometriosis are uncertain, due to
paucity of sufficiently large, high-quality studies. Current guidelines,
consensus statements and recommendations acknowledge this def-
icit, but continue to emphasize the benefits of HRT over the
undefined risks for severely symptomatic women (Al Kadri et al.,
2009; Johnson and Hummelshoj, 2013; Dunselman et al., 2014).
However, many women with endometriosis who undergo surgical
menopause are given hormonal replacement therapy as a prophylaxis
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before the development of menopausal symptoms. For these
women, clinicians must balance the benefits to bone (Cauley et al.,
2003) and cardiovascular health (Rossouw et al., 2007), particularly
for younger patients, against the potential risks of recurrence or
malignancy.
It is important to note that recurrence is possible even in the
absence of HRT. There are reports of endometriosis recurrence in
women not on any hormonal treatment (Fujiu et al., 2010; Bhat et al.,
2014). In these women, other risk factors such as hyperestrogenemia
and obesity may play larger roles in the pathogenesis (Punnonen
et al., 1980). Incomplete definitive surgery and residual ovarian rem-
nants are also considered risks factor for the development of post-
menopausal endometriosis (Dmowski et al., 1988). It remains to be
confirmed whether a genetic predisposition together with environ-
mental factors, medication, or fat distribution increase the risk of
endometriosis after menopause, as has been shown for premenopau-
sal women (Rahmioglu et al., 2015a,b).
Malignant transformation
Our search retrieved 20 case reports and series (25 patients) of malig-
nant transformation of endometriotic foci following HRT. Of 25
patients, 22 had undergone surgical menopause, which was not surpris-
ing given that many women had a history of severe disease with
comorbidities such as leiomyomas and adenomyosis. Unopposed oes-
trogens were implicated in 19 patients, with conjugated equine oestro-
gens implicated in eight patients and oestradiol implants in four
patients. Currently there are no data to indicate the absolute risk of
malignant transformation in this group of women. It is likely that this is
a rare outcome, but better data are urgently needed to enable women
to make an informed decision about menopausal management.
Fortunately, tumours arising from endometriosis are typically low grade
and have a better prognosis (Heaps et al., 1990); only three deaths
were reported in the literature identified by our search. Mortality was
noted in the two case reports with patients who had histories of
severe endometriosis and complicating factors, including increased age
(Duun et al., 1993) or multiple malignancies (Reimnitz et al., 1988)
Considerations regarding type and timing
of HRT
Adjusting the type and timing of the treatment plan may mitigate the
potential risks of HRT highlighted by our case reports and series.
Type: oestrogen-only, combined or tibolone
Our review retrieved evidence on three main types of HRT:
oestrogen-only, combined and tibolone.
A consistent theme among the case reports is the predominance
of oestrogen-only HRT in women with recurrence or malignancy.
The majority of case reports concerned women taking unopposed
oestrogens, particularly conjugated equine oestrogens. This is not
surprising given the strong association between unopposed oestro-
gens and endometrial cancer (Sjogren et al., 2016). As a result, cur-
rent recommendations favour continuous combined preparations
instead of unopposed oestrogens for women with a history of endo-
metriosis, but the evidence remains sparse (Soliman and Hillard,
2006; Oxholm et al., 2007). We identified a single observational
study that addressed this issue, including only 90 women
(Rattanachaiyanont et al., 2003). Although the only women who
developed recurrent symptoms were those taking oestrogen-only
HRT, the study was retrospective and unable to demonstrate statis-
tically significant differences between the groups. The authors sug-
gested that combined HRT preparations might be the most
appropriate for women with endometriosis who are using HRT. Large,
randomized trials or observational studies with appropriate statistical
power are clearly needed to clarify this question. Further research is
urgently needed given the increased risk of breast cancer associated
with combined HRT, although it is mostly in the older age group,
which has been attributed to progestins (Chlebowski et al., 2013).
Tibolone therapy has also been associated with recurrence of
endometriosis (Sundar et al., 2007). One RCT included in our review
considered the use of tibolone, as compared with combined HRT,
but the results should be interpreted with caution given the small
sample size (n = 21). Fedele and colleagues (1999) concluded that
tibolone (which typically has an oestrogenic effect on climacteric
symptoms and bone, yet a progestogenic effect on tissues) might be
a safer alternative to traditional HRT in patients with residual endo-
metriotic disease, but no statistically significant difference was seen
between the groups.
Notably, one case report highlights the importance of asking
patients about their use of supplements or complementary/alterna-
tive medication. Five-year use of a highly concentrated isoflavone sup-
plement was associated with florid recurrence of endometriosis and
ureteral malignant mullerian carcinosarcoma (Noel et al., 2006). This
report raises further concerns over the use of phytoestrogens in
postmenopausal women with a history of endometriosis (Cotroneo
and Lamartiniere, 2001), despite some clinical and animal literature
suggesting a reduced risk of endometriosis with dietary isoflavones
(Tsuchiya et al., 2007; Yavuz et al., 2007). Given the high prevalence
of supplement use, it is important to further explore the relationship
between phytoestrogens and endometriosis.
Timing: initiation and duration
Data are also lacking on the optimal time to commence HRT follow-
ing surgical menopause. We identified a retrospective study in this
area, comparing immediate (within 6 weeks of surgery) to delayed
(≥6 weeks following surgery) commencement of HRT (Hickman
et al., 1998). Although the crude incidence of recurrence was not dif-
ferent between the groups, increased recurrence was noted for
women who delayed starting HRT after adjusting for confounders
(AFS score at time of surgery, age at hysterectomy and postoperative
adjunctive use of medroxyprogesterone). The authors themselves
note the strong likelihood of bias in this observational study; it is
probable that deferring the start of HRT would have been recom-
mended to women felt to be at higher risk of recurrent symptoms.
Additionally, we retrieved a non-comparative cohort study
(Arumugam and Damodaran, 1998), which prospectively followed
eight women who received conjugated oestrogens in the form of oral
daily Premarin 5 months post surgical menopause, and five women
who received oestrogens 3 months post surgical menopause.
Women from both groups remained well and asymptomatic at
6-month follow-ups, yet clearly a much longer follow-up duration is
necessary to be able to accurately assess risk of recurrence. The
authors of this study also did not specify any symptoms or provide
additional detail on patient status, and thus the evidence provided by
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this study was assessed as very low quality. Randomized trials are
clearly needed to avoid this risk of bias, and have the potential to
answer this question robustly.
Our search retrieved no studies investigating the total time for which
women with histories of endometriosis should be treated. This is unfortu-
nate given that it takes time to acquire mutations in endometriotic tissue,
and thus duration of HRT therapy may have a large impact on probability
of malignancy. Our systematic review also retrieved case reports of malig-
nant transformation 4 and 8 years after stopping HRT treatment
(Karanjgaokar et al., 2009), indicating that hormone replacement may
either still have effects years after discontinuation or that the use of HRT
is only one factor in malignant transformation of endometriosis.
Conclusion
Endometriosis is not exclusively a condition of the reproductive
phase. Existing guidelines in this area emphasize the lack of evidence,
but suggest that women should not be denied HRT treatment simply
because of a history of endometriosis (Al Kadri et al., 2009;
Dunselman et al., 2014). Our review indicates that women with a
history of endometriosis should be carefully counselled about the
possibility of disease recurrence after the menopause (Fig. 2).
Although the absolute risk is unclear and likely to be low, women
should be advised to seek help if they experience endometriosis-like
symptoms, rather than suffer in silence. Furthermore, clinicians
should adopt a cautious approach in cases of recurrence, keeping in
mind the possibility of malignant transformation. For postmenopausal
women with recurrent, treatment-resistant symptoms, consideration
should be given to obtaining tissue for histology in order to exclude
the possibility of malignancy, especially if other unusual or suspicious
symptoms are present.
Although this review highlights potential risks of HRT, its substan-
tial benefits should not be overlooked. In particular, the benefits may
outweigh the costs of HRT for women with an early or surgical
menopause. HRT has been shown to enhance cortical volumetric
bone mineral density and compressive strength (Mikkola et al., 2011;
Kuh et al., 2016). Additionally, studies have shown a reduced risk of
coronary heart disease when hormonal therapy is administered to
women with early natural or surgical menopause (Parker et al.,
2009). Importantly, unilateral or bilateral oophorectomy prior to the
onset of natural menopause is associated with an increased risk of
Figure 2 Suggested clinical approach to postmenopausal patients with a history of endometriosis.
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dementia and cognitive impairment (Rocca et al., 2007); however,
these risks may be reduced if HRT is administered up until the aver-
age age of natural menopause (Rocca et al., 2014).
As with any woman commencing HRT, a full and frank discussion
should be held about the risks and benefits of this treatment.
Currently, clinicians must balance the benefits and risks of HRT, with
attention to individual risk factors (age and BMI), and choose appro-
priate therapies directed at specific menopausal symptoms. Patients
must be actively involved in the decision process, and understand our
limitations as providers to quantify specific risks. Women should be
advised that there are no robust data to indicate whether HRT
changes the risk of disease recurrence or malignant transformation.
Small studies have suggested the possibility of increased recurrence in
women who take HRT, in particular unopposed oestrogen. Some
authors advocate the use of combined HRT for women with a his-
tory of endometriosis, to minimize the risk of recurrence (Moen
et al., 2010; Dunselman et al., 2014), but there are still risks with
combined oestrogen-progestin hormone therapy. These include an
elevated risk of breast cancer both during and post-intervention
mostly in older women (Chlebowski et al., 2015). Therefore care
must be individualized, with the woman’s personal and family history
taken into account.
There are many promising areas for future research in this group
of women. Our search retrieved no papers on the use of alternative
selective oestrogen receptor modulators (SERMs) in postmenopausal
patients with histories of endometriosis. We are aware of studies
testing the gynaecologic safety of SERMS such as ospemifene and
bazedoxifene, and combining these agents with oestrogens (especially
bazedoxifene/conjugated oestrogens) (Mirkin et al., 2016). Such stud-
ies have been promising, and may represent a future alternative to
conventional HRT for our cohort.
Summary
Our review highlights an important and severely under-researched
area of gynaecology. The prevalence of endometriosis means that
both specialists and general practitioners will inevitably encounter
women with a history of this condition who are facing the dilemma of
managing the menopause. Many women will have suffered years of
debilitating symptoms before diagnosis, and then proceeded to
undergo multiple treatments and operations in an attempt to regain
some quality of life. These women deserve to have accurate, indivi-
dualized and specific information about the risk of recurrence with
different menopausal treatments, so that they can make an informed
decision about their care.
Supplementary data
Supplementary data are available at Human Reproduction Update
online.
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